Addison Christina L, Belperio John A, Burdick Marie D, Strieter Robert M
Departments of Medicine, Pathology, and Pediatrics, Division of Pulmonary and Critical Care Medicine, UCLA School of Medicine, Los Angeles CA, 90024-1922 USA.
BMC Cancer. 2004 Jun 23;4:28. doi: 10.1186/1471-2407-4-28.
The Duffy antigen receptor for chemokines (DARC) is known to be a promiscuous chemokine receptor that binds a variety of CXC and CC chemokines in the absence of any detectable signal transduction events. Within the CXC group of chemokines, DARC binds the angiogenic CXC chemokines including IL-8 (CXCL8), GROalpha (CXCL1) and ENA-78 (CXCL5), all of which have previously been shown to be important in non-small cell lung carcinoma (NSCLC) tumor growth. We hypothesized that overexpression of DARC by a NSCLC tumor cell line would result in the binding of the angiogenic ELR+ CXC chemokines by the tumor cells themselves, and thus interfere with the stimulation of endothelial cells and induction of angiogenesis by the tumor cell-derived angiogenic chemokines.
NSCLC tumor cells that constitutively expressed DARC were generated and their growth characteristics were compared to control transfected cells in vitro and in vivo in SCID animals. We found that tumors derived from DARC-expressing cells were significantly larger in size than tumors derived from control-transfected cells. However, upon histological examination we found that DARC-expressing tumors had significantly more necrosis and decreased tumor cellularity, as compared to control tumors. Expression of DARC by NSCLC cells was also associated with a decrease in tumor-associated vasculature and a reduction in metastatic potential.
The expression of DARC in the context of NSCLC tumors may act as a chemokine decoy receptor and interferes with normal tumor growth and chemokine-induced tumor neovascularization.
趋化因子的达菲抗原受体(DARC)是一种杂乱的趋化因子受体,在没有任何可检测到的信号转导事件的情况下,它能结合多种CXC和CC趋化因子。在CXC趋化因子组中,DARC能结合促血管生成的CXC趋化因子,包括白细胞介素-8(CXCL8)、生长调节致癌基因α(CXCL1)和ENA-78(CXCL5),所有这些趋化因子此前已被证明在非小细胞肺癌(NSCLC)肿瘤生长中起重要作用。我们推测,NSCLC肿瘤细胞系中DARC的过表达会导致肿瘤细胞自身结合促血管生成的ELR+CXC趋化因子,从而干扰肿瘤细胞衍生的促血管生成趋化因子对内皮细胞的刺激和血管生成的诱导。
构建了组成性表达DARC的NSCLC肿瘤细胞,并在体外和SCID动物体内将其生长特性与对照转染细胞进行比较。我们发现,源自表达DARC细胞的肿瘤在大小上显著大于源自对照转染细胞的肿瘤。然而,组织学检查发现,与对照肿瘤相比,表达DARC的肿瘤坏死明显更多,肿瘤细胞密度降低。NSCLC细胞中DARC的表达还与肿瘤相关脉管系统的减少和转移潜能的降低有关。
NSCLC肿瘤中DARC的表达可能作为一种趋化因子诱饵受体,干扰正常肿瘤生长和趋化因子诱导肿瘤新生血管形成。